Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied
in the past decade, but effective approaches to prevent and treat this disease are limited …

Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

Although cardiologists have long treated patients with coronary artery disease (CAD) and
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …

Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional
protein which, besides its catalytic activity, also functions as a binding protein and a ligand …

Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and
associated with considerable morbidity and mortality. Significant advances have recently …

The heart failure epidemic is growing and its prevention, in order to reduce associated
hospital readmission rates and its clinical and economic burden, is a key issue in modern …

Heart failure (HF) is a growing public health issue. As many as 1 in 5 people are expected to
develop HF during their lifetime, 1 with an estimated 63 million people affected worldwide. 2 …